 |
|
Treatment of Neuromyelitis Optica With Mycophenolate MofetilRetrospective Analysis of 24 Patients
Anu Jacob, MD;
Marcelo Matiello, MD;
Brian G. Weinshenker, MD;
Dean M. Wingerchuk, MD;
Claudia Lucchinetti, MD;
Elizabeth Shuster, MD;
Jonathan Carter, MD;
B. Mark Keegan, MD;
Orhun H. Kantarci, MD;
Sean J. Pittock, MD
Arch Neurol. 2009;66(9):1128-1133.
Background Neuromyelitis optica (NMO) is the first inflammatory autoimmune demyelinating disease of the central nervous system for which a specific antigenic target has been identified; the marker autoantibody NMO-IgG specifically recognizes the astrocytic water channel aquaporin 4. Current evidence strongly suggests that NMO-IgG may be pathogenic. Since disability accrues incrementally related to attacks, attack prevention with immunosuppressive therapy is the mainstay of preventing disability.
Objective To evaluate the efficacy and safety of mycophenolate mofetil therapy in NMO spectrum disorders.
Design Retrospective case series with prospective telephone follow-up.
Setting Mayo Clinic Health System.
Patients Twenty-four patients with NMO spectrum disorders (7 treatment-naive).
Intervention Mycophenolate mofetil (median dose of 2000 mg per day).
Main Outcome Measures Annualized relapse rates and disability (Expanded Disability Status Scale).
Results At a median follow-up of 28 months (range, 18-89 months), 19 patients (79%) were continuing treatment. The median duration of treatment was 27 months (range, 1-89 months). The median annualized posttreatment relapse rate was lower than the pretreatment rate (0.09; range, 0-1.5; and 1.3; range, 0.23-11.8, respectively; P < .001). Disability stabilized or decreased in 22 of 24 patients (91%). One patient died of disease complications during follow-up. Six patients (25%) noted adverse effects during treatment with mycophenolate.
Conclusion Mycophenolate is associated with reduction in relapse frequency and stable or reduced disability in patients with NMO spectrum disorders.
Author Affiliations: Departments of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota (Drs Jacob, Matiello, Weinshenker, Lucchinetti, Keegan, Kantarci, and Pittock); Mayo Clinic, Scottsdale, Arizona (Drs Wingerchuk and Carter); and Mayo Clinic, Jacksonville, Florida (Dr Shuster). Dr Jacob is currently a consultant at the Walton Centre, Liverpool, England.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Neurology
Arch Neurol. 2009;66(9):1056-1057.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Impact of rituximab on relapse rate and disability in neuromyelitis optica
Bedi et al.
Mult Scler 2011;17:1225-1230.
ABSTRACT
| FULL TEXT
AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems
Siritho et al.
Neurology 2011;77:827-834.
ABSTRACT
| FULL TEXT
Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica
Costanzi et al.
Neurology 2011;77:659-666.
ABSTRACT
| FULL TEXT
Efficacy and Safety of Mitoxantrone in Patients With Highly Relapsing Neuromyelitis Optica
Kim et al.
Arch Neurol 2011;68:473-479.
ABSTRACT
| FULL TEXT
Current and future treatment approaches for neuromyelitis optica
Collongues and de Seze
Therapeutic Advances in Neurological Disorders 2011;4:111-121.
ABSTRACT
Neuromyelitis optica and NMO-IgG in European pediatric patients
Huppke et al.
Neurology 2010;75:1740-1744.
ABSTRACT
| FULL TEXT
Neuromyelitis Optica Treatment: Analysis of 36 Patients
Bichuetti et al.
Arch Neurol 2010;67:1131-1136.
ABSTRACT
| FULL TEXT
|
